Vanillin Shows Promise as a Treatment for Chronic Wounds

Vanillin Shows Promise for Chronic Wound Healing in Laboratory Studies

Vanillin, the compound responsible for vanilla’s familiar flavor, could have a future in treatments for chronic wounds that are difficult to heal, according to a new review published in the International Journal of Pharmacy. Read the review paper.

Vanillin’s biological properties

“Vanillin is one of the most widely used flavoring compounds around the world, and is commonly reported to be second only to saffron in economic importance among flavorants,” said Professor Krasimir Vasilev and colleagues at Flinders University.

“It is widely incorporated into food and beverage products and is also used in the pharmaceutical and cosmetic industries.”

Commercial vanillin is produced through three main routes: extraction of natural vanillin from plants of the genus Vanilla; biotechnological production from substrates such as ferulic acid, glucose, and lignin through enzymatic conversion or de novo microbial fermentation using engineered bacterial strains; and chemical synthesis from petrochemical precursors such as eugenol and guaiacol.

“Beyond its established role as a flavoring and aroma component, vanillin is increasingly recognized for its diverse biological activities, stimulating interest in biomedical research.”

In their review, Professor Vasilev and his co-authors assessed vanillin as a food-derived molecule with potential biomedical applications. They focused on its chemical origin, biological activity, and use in functional preparations for chronic wound repair.

How vanillin may support wound healing

Laboratory studies have shown that vanillin can neutralize reactive oxygen species—unstable molecules that can accumulate in chronic wounds and delay healing.

Vanillin also reduces inflammatory signals, including several cytokines and enzymes associated with inflammation. In addition, it has demonstrated antibacterial effects.

Because vanillin’s aldehyde groups readily react with amino groups, polymers such as chitosan—a material derived from seashells—can be incorporated into soft gels and bandages.

The researchers cataloged dozens of vanillin-based formulations, including hydrogels, porous scaffolds, nanofiber mats, and nanoparticles. Several experiments were conducted in rats or mice with infections, diabetes, or full-thickness wounds.

Animal studies show high wound-closure rates

One bilayer dressing combining vanillin with growth factors achieved a wound-closure rate of 96.4% within 14 days in animals. A vanillin-modified chitosan material achieved approximately 94% wound closure.

These results come from independent animal studies and do not represent results from human clinical trials.

Important challenges remain

Vanillin-based wound treatments have not yet been evaluated using standardized tests. Researchers also know little about how deeply vanillin penetrates the skin, how long it remains in wounds, or how it is eliminated after topical application.

The effects of vanillin also appear to depend on dosage. One study found that concentrations above a certain level were toxic to cells, suggesting that treatments may need to remain within a narrow therapeutic range.

Another challenge is that skin and immune cells rapidly convert vanillin into related compounds such as vanillic acid. This conversion may help explain some of the benefits observed in laboratory studies.

The authors conclude that vanillin is a promising candidate for chronic wound healing and tissue regeneration, but they emphasize that it remains insufficiently studied.

“With a collaborative effort between academia, clinicians, and industry, vanillin has the potential to evolve from an underutilized bioactive substance to a clinically applicable component of the next generation of wound and regenerative therapies,” Professor Vasilev concluded.

_____

Borislav Stoilov et al. 2026. Vanillin as a bioactive ingredient in biomedical preparations for chronic wound healing and tissue regeneration. International Journal of Pharmacy 702: 127263; doi: 10.1016/j.ijpharm.2026.127263.